Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus

Diabetes Care

Volumn 34, Issue 6, 2011, Pages

  Sacks, David B ^a   Arnold, Mark ^b   Bakris, George L ^c   Bruns, David E ^d   Horvath, Andrea Rita ^e   Kirkman, M Sue ^f   Lernmark, Ake ^g   Metzger, Boyd E ^h   Nathan, David M ⁱ  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b E11 SSH   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f AMERICAN DIABETES ASSOCIATION   (United States)

^g LUND UNIVERSITY   (Sweden)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AUTOANTIBODY; C PEPTIDE; CREATININE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOSE; GLUTAMATE DECARBOXYLASE 65; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HLA D ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INSULIN; INSULIN ANTIBODY; KETONE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; ORAL ANTIDIABETIC AGENT; PROINSULIN; SULFONYLUREA; TRANSCRIPTION FACTOR PDX 1;

ALBUMINURIA; AUTOIMMUNITY; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; EVIDENCE BASED MEDICINE; GENETIC SCREENING; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; JUVENILE DIABETES MELLITUS; KETONURIA; LABORATORY DIAGNOSIS; LABORATORY TEST; LIFE EXPECTANCY; MEDICAL SOCIETY; METABOLIC DISORDER; MINIMALLY INVASIVE PROCEDURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; PRICK TEST; PROGNOSIS; QUALITY CONTROL; REVIEW; RISK FACTOR; SELF MONITORING;

BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES;

EID: 80051981694     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-9998     Document Type: Review

References (378)

1. ADA. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97
2. Castano L., Eisenbarth G.S. Type-I diabetes: A chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 1990;8:647-79 (Pubitemid 20135642)
3. Reaven G.M. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607 (Pubitemid 19004941)
4. Sacks D.B., McDonald J.M. The pathogenesis of type II diabetes mellitus. A polygenic disease. Am J Clin Pathol 1996;105:149-56 (Pubitemid 26047473)
5. Balasubramanyam A., Garza G., Rodriguez L., Hampe C.S., Gaur L., Lernmark A., Maldonado M.R. Accuracy and predictive value of classification schemes for ketosisprone diabetes. Diabetes Care 2006;29:2575-9 (Pubitemid 44912181)
6. I.D.F. Diabetes Atlas. 3rd ed. Brussels: IDF; 2008
7. Cowie C.C., Rust K.F., Byrd-Holt D.D., Eberhardt M.S., Flegal K.M., Engelgau M.M., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-8 (Pubitemid 44125920)
8. Cowie C.C., Rust K.F., Ford E.S., Eberhardt M.S., Byrd-Holt D.D., Li C., et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287-94
9. Chan J.C., Malik V., Jia W., Kadowaki T., Yajnik C.S., Yoon K.H., Hu F.B. Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40
10. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101
11. ADA. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
12. Nathan D.M. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676-85 (Pubitemid 23157351)
13. Roglic G., Unwin N., Bennett P.H., Mathers C., Tuomilehto J., Nag S., et al. The burden of mortality attributable to diabetes: Realistic estimates for the year 2000. Diabetes Care 2005;28:2130-5 (Pubitemid 41242456)
14. Sacks D.B., Bruns D.E., Goldstein D.E., Maclaren N.K., McDonald J.M., Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-72 (Pubitemid 34174577)
15. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57
16. WHO. WHO Expert Committee on Diabetes Mellitus: Second report. World Health Org. Tech Rep Ser 1980;646:1-80
17. Engelgau M.M., Thompson T.J., Herman W.H., Boyle J.P., Aubert R.E., Kenny S.J., et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997;20:785-91 (Pubitemid 27202529)
18. McCance D.R., Hanson R.L., Charles M.A., Jacobsson L.T., Pettitt D.J., Bennett P.H., Knowler W.C. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994;308:1323-8.
19. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: WHO; 2006
20. The International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34
21. ADA. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33 (Suppl. 1):S11-61
22. ADA. Tests of glycemia in diabetes. Diabetes Care 2001;24(Suppl. 1):S80-2
23. IDF. Task Force. Global guideline for type 2 diabetes. Brussels: IDF; 2005. p 1-11
24. Saudek C.D., Herman W.H., Sacks D.B., Bergenstal R.M., Edelman D., Davidson M.B. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008;93:2447-53 (Pubitemid 352008502)
25. ADA. Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381-9
26. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403 (Pubitemid 34437694)
27. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50 (Pubitemid 32378388)
28. Icks A., Rathmann W., Haastert B., John J., Löwel H., Holle R., Giani G. Costeffectiveness of type 2 diabetes screening: Results from recently published studies. Gesundheitswesen 2005;67(Suppl. 1):S167-S171
29. Perry R.C., Shankar R.R., Fineberg N., McGill J., Baron A.D. HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: The Early Diabetes Intervention Program(EDIP). Diabetes Care 2001;24:465-471 (Pubitemid 32198414)
30. Jesudason D.R., Dunstan K., Leong D., Wittert G.A. Macrovascular risk and diagnostic criteria for type 2 diabetes: Implications for the use of FPG and HbA1c for cost-effective screening. Diabetes Care 2003;26:485-490 (Pubitemid 36929079)
31. Dallo F.J., Weller S.C. Effectiveness of diabetes mellitus screening recommendations. Proc Natl Acad Sci U S A 2003;100:10574-9.
32. Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-1763
33. Hoerger T.J., Harris R., Hicks K.A., Donahue K., Sorensen S., Engelgau M. Screening for type 2 diabetes mellitus: A cost-effectiveness analysis. Ann Intern Med 2004;140:689-699
34. Glumer C., Yuyun M., Griffin S., Farewell D., Spiegelhalter D., Kinmonth A.L., Wareham N.J. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006;49:1536-1544 (Pubitemid 43848089)
35. Kahn R., Alperin P., Eddy D, Borch- Johnsen K, Buse J, Feigelman J, et al. Age at initiation and frequency of screening to detect type 2 diabetes: A cost-effectiveness analysis. Lancet 2010;375:1365-1374
36. Greenberg R.A., Sacks D.B. Screening for diabetes: Is it warranted? Clin Chim Acta 2002;315:61-69 (Pubitemid 33145249)
37. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167 (Pubitemid 37339514)
38. Forouhi N.G., Balkau B., Borch-Johnsen K., Dekker J., Glumer C., Qiao Q., et al. The threshold for diagnosing impaired fasting glucose: A position statement by the European Diabetes Epidemiology Group. Diabetologia 2006;49:822-827
39. Tai E.S., Goh S.Y., Lee J.J., Wong M.S., Heng D., Hughes K., et al. Lowering the criterion for impaired fasting glucose: Impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 2004;27:1728-1734 (Pubitemid 38857451)
40. Gabir M.M., Hanson R.L., Dabelea D., Imperatore G., Roumain J., Bennett P.H., Knowler W.C. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000;23:1108-1112 (Pubitemid 30616797)
41. Tirosh A., Shai I., Tekes-Manova D., Israeli E., Pereg D., Shochat T., et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005;353:1454-1462 (Pubitemid 41400919)
42. DCCT. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-983
43. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
44. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
45. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653 (Pubitemid 41817713)
46. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
47. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., Golden S.H. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-431
48. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772
49. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
50. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. Jr, Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559 (Pubitemid 351831356)
51. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
52. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
53. Berg A.H., Sacks D.B. Haemoglobin A1c analysis in the management of patients with diabetes: From chaos to harmony. J Clin Pathol 2008;61:983-987
54. Howe-Davies S., Simpson R.W., Turner R.C. Control of maturity-onset diabetes by monitoring fasting blood glucose and body weight. Diabetes Care 1980;3:607-610 (Pubitemid 11245826)
55. Muir A., Howe-Davies S.A., Turner R.C. General practice care of non-insulindependent diabetes with fasting blood glucose measurements. Am J Med 1982;73:637-640 (Pubitemid 13234216)
56. Harris M.I. Undiagnosed NIDDM: Clinical and public health issues. Diabetes Care 1993;16: 642-652 (Pubitemid 23097217)
57. Troisi R.J., Cowie C.C., Harris M.I. Diurnal variation in fasting plasma glucose: Implications for diagnosis of diabetes in patients examined in the afternoon. JAMA 2000;284:3157-3159 (Pubitemid 32039079)
58. Bruns D.E., Knowler W.C. Stabilization of glucose in blood samples: Why itmatters. Clin Chem 2009;55:850-852
59. Chan A.Y., Swaminathan R., Cockram C.S. Effectiveness of sodium fluoride as a preservative of glucose in blood. Clin Chem 1989;35:315-317 (Pubitemid 19075618)
60. Ladenson J.H. Nonanalytical sources of variation in clinical chemistry results. In: Sonnenwirth A, Jarett L, eds. Clinical laboratory methods and diagnosis. St. Louis: C.V. Mosby Co.; 1980. p 149-192
61. Sacks D.B. Carbohydrates. In: Burtis CA, Ash-wood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. St. Louis: Elsevier Saunders; 2006. p 837- 902
62. Gambino R., Piscitelli J., Ackattupathil T.A., Theriault J.L., Andrin R.D., Sanfilippo M.L., Etienne M. Acidification of blood is superior to sodium fluoride alone as an inhibitor of glycolysis. Clin Chem 2009;55:1019-1021
63. Ladenson J.H., Tsai L.M., Michael J.M., Kessler G., Joist J.H. Serum versus heparinized plasma for eighteen common chemistry tests: Is serum the appropriate specimen? Am J Clin Pathol 1974;62:545-552
64. Stahl M., Jorgensen L.G., Hyltoft Petersen P., Brandslund I., De Fine Olivarius N., Borch-Johnsen K. Optimization of preanalytical conditions and analysis of plasma glucose. 1. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001;61:169-179 (Pubitemid 32417650)
65. Carstensen B., Lindstrom J., Sundvall J., Borch-Johnsen K., Tuomilehto J. Measurement of blood glucose: Comparison between different types of specimens. Ann Clin Biochem 2008;45:140-148 (Pubitemid 351724584)
66. Boyanton B.L. Jr, Blick K.E. Stability studies of twenty-four analytes in human plasma and serum. Clin Chem 2002;48:2242-2247 (Pubitemid 35397569)
67. Miles R.R., Roberts R.F., Putnam A.R., Roberts W.L. Comparison of serum and heparinized plasma samples for measurement of chemistry analytes. Clin Chem 2004;50:1704-1705
68. Larsson-Cohn U. Differences between capillary and venous blood glucose during oral glucose tolerance tests. Scand J Clin Lab Invest 1976;36:805-808
69. Lind T., De Groot H.A., Brown G., Cheyne G.A. Observations on blood glucose and insulin determinations. Br Med J 1972;3:320-323
70. Sacks D.B. Carbohydrates. In: Burtis CA, Ash-wood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. St. Louis: Elsevier Saunders. Accepted; forthcoming 2012
71. Tchobroutsky G. Blood glucose levels in diabetic and non-diabetic subjects. Diabetologia 1991;34:67-73
72. Blunt B.A., Barrett-Connor E., Wingard D.L. Evaluation of fasting plasma glucose as screening test for NIDDM in older adults. Rancho Bernardo Study. Diabetes Care 1991;14:989-993
73. DECODE. Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care 1999;22:1667-1671
74. Ferrannini E., Vichi S., Beck-Nielsen H., Laakso M., Paolisso G., Smith U. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996;45:947-953
75. Imbeault P., Prins J.B., Stolic M., Russell A.W., O'Moore-Sullivan T., Despres J.P., et al. Aging per se does not influence glucose homeostasis: In vivo and in vitro evidence. Diabetes Care 2003;26:480-484 (Pubitemid 36929078)
76. Miller W.G., Myers G.L., Ashwood E.R., Killeen A.A., Wang E., Ehlers G.W., et al. State of the art in trueness and interlaboratory harmonization for 10 analytes in general clinical chemistry. Arch Pathol Lab Med 2008;132:838-846 (Pubitemid 351632864)
77. Fraser C.G., Petersen P.H. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999;45:321-323 (Pubitemid 29114165)
78. Stockl D., Baadenhuijsen H., Fraser C.G., Libeer J.C., Petersen P.H., Ricos C. Desirable routine analytical goals for quantities assayed in serum. Discussion paper from the members of the External Quality Assessment (EQA) Working Group A on analytical goals in laboratory medicine. Eur J Clin Chem Clin Biochem 1995;33:157-169
79. Fraser C.G. The necessity of achieving good laboratory performance. Diabet Med 1990;7:490-493 (Pubitemid 20199792)
80. Olefsky J.M., Reaven G.M. Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes 1974;23:449-453
81. Widjaja A., Morris R.J., Levy J.C., Frayn K.N., Manley S.E., Turner R.C. Withinand between-subject variation in commonly measured anthropometric and biochemical variables. Clin Chem 1999;45:561-566 (Pubitemid 29165967)
82. Sebastian-Gambaro M.A., Liron-Hernandez F.J., Fuentes-Arderiu X. Intra- and interindividual biological variability data bank. Eur J Clin Chem Clin Biochem 1997;35:845-852 (Pubitemid 27510862)
83. Mooy J.M., Grootenhuis P.A., De Vries H., Kostense P.J., Popp-Snijders C., Bouter L.M., Heine R.J. Intraindividual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: The Hoorn Study. Diabetologia 1996;39:298-305 (Pubitemid 26066801)
84. Selvin E., Crainiceanu C.M., Brancati F.L., Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007;167:1545-1551 (Pubitemid 47124186)
85. Lacher D.A., Hughes J.P., Carroll M.D. Estimate of biological variation of laboratory analytes based on the Third National Health and Nutrition Examination Survey. Clin Chem 2005;51:450-452 (Pubitemid 40175818)
86. Westgard QC. Desirable specifications for total error, imprecision, and bias, derived from biologic variation. Available from http://www.westgard.com/ biodatabase1.htm. Accessed July 2009
87. Howanitz P.J., Cembrowski G.S., Steindel S.J., Long T.A. Physician goals and laboratory test turnaround times. A College of American Pathologists Q-Probes study of 2763 clinicians and 722 institutions. Arch Pathol Lab Med 1993;117:22-28 (Pubitemid 23027000)
88. Van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-1367
89. ADA. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32(Suppl. 1):S13-S61
90. Harris M.I., Cowie C.C., Howie L.J. Selfmonitoring of blood glucose by adults with diabetes in the United States population. Diabetes Care 1993;16:1116-1123 (Pubitemid 23215399)
91. CDC. Self-monitoring of blood glucose among adults with diabetes - United States, 1997-2006. MMWR Morb Mortal Wkly Rep 2007;56:1133-1137
92. ADA. Self-monitoring of blood glucose. Diabetes Care 1996;19(Suppl. 1):S62-S66
93. ADA. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34 (Suppl. 1):S11-S61
94. Ipp E., Aquino R.L., Christenson P. Point: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulinThe sanguine approach. Diabetes Care 2005;28:1528-1530 (Pubitemid 40756732)
95. Davidson M.B. Counterpoint: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulinA waste of money. Diabetes Care 2005;28:1531-1533 (Pubitemid 40756733)
96. Faas A., Schellevis F.G., Van Eijk J.T. The efficacy of self-monitoring of blood glucose in NIDDMsubjects. A criteria-based literature review. Diabetes Care 1997;20:1482-1486 (Pubitemid 27366830)
97. Coster S., Gulliford M.C., Seed P.T., Powrie J.K., Swaminathan R. Self-monitoring in type 2 diabetes mellitus: A meta-analysis. Diabet Med 2000;17:755-761 (Pubitemid 32000973)
98. Harris M.I. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:979-982 (Pubitemid 33716362)
99. Davis W.A., Bruce D.G., Davis T.M. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 2006;29:1764-1770 (Pubitemid 44156627)
100. Guerci B., Drouin P., Grange V., Bougneres P., Fontaine P., Kerlan V., et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: The Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003;29:587-594 (Pubitemid 38082160)
101. Davidson M.B., Castellanos M., Kain D., Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: A blinded, randomized trial. Am J Med 2005;118:422-425 (Pubitemid 40461003)
102. Franciosi M., Pellegrini F., De Berardis G., Belfiglio M., Di Nardo B., Greenfield S., et al. Self-monitoring of blood glucose in non-insulin-treated diabetic patients: A longitudinal evaluation of its impact on metabolic control. Diabet Med 2005;22:900-906 (Pubitemid 40942589)
103. Karter A.J., Parker M.M., Moffet H.H., Spence M.M., Chan J., Ettner S.L., Selby J.V. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29:1757-1763 (Pubitemid 44156626)
104. Martin S., Schneider B., Heinemann L., Lodwig V., Kurth H.J., Kolb H., Scherbaum W.A. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: An epidemiological cohort study. Diabetologia 2006;49:271-278 (Pubitemid 43185395)
105. Welschen L.M., Bloemendal E., Nijpels G., Dekker J.M., Heine R.J., Stalman W.A., Bouter L.M. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database Syst Rev 2005:CD005060
106. Welschen L.M., Bloemendal E., Nijpels G., Dekker J.M., Heine R.J., Stalman W.A., Bouter L.M. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: A systematic review. Diabetes Care 2005;28:1510-1517 (Pubitemid 40756728)
107. Farmer A., Wade A., Goyder E., Yudkin P., French D., Craven A., et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: Open parallel group randomised trial. BMJ 2007;335:132
108. Simon J., Gray A., Clarke P., Wade A., Neil A., Farmer A. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: Economic evaluation of data from the DiGEM trial. BMJ 2008;336:1177-1180 (Pubitemid 351809279)
109. O'Kane M.J., Bunting B., Copeland M., Coates V.E. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): Randomised controlled trial. BMJ 2008;336:1174-1177 (Pubitemid 351809278)
110. Allemann S., Houriet C., Diem P., Stettler C. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: A systematic review and metaanalysis. Curr Med Res Opin 2009;25:2903-2913
111. Poolsup N., Suksomboon N., Rattanasookchit S. Meta-analysis of the benefits of selfmonitoring of blood glucose on glycemic control in type 2 diabetes patients: An update. Diabetes Technol Ther 2009;11:775-784
112. Montori V.M., Fernández-Balsells M. Glycemic control in type 2 diabetes: Time for an evidence-based about-face? Ann Intern Med 2009;150:803-808
113. Gerich J.E., Mokan M., Veneman T., Korytkowski M., Mitrakou A. Hypoglycemia unawareness. Endocr Rev 1991;12:356-371
114. Tang Z., Lee J.H., Louie R.F., Kost G.J. Effects of different hematocrit levels on glucose measurements with handheld meters for point-of-care testing. Arch Pathol Lab Med 2000;124:1135-1140 (Pubitemid 30650312)
115. ADA. Consensus statement on self-monitoring of blood glucose. Diabetes Care 1994;17:81-86
116. Tate P.F., Clements C.A., Walters J.E. Accuracy of home blood glucose monitors. Diabetes Care 1992;15:536-538
117. Chan J.C., Wong R.Y., Cheung C.K., Lam P., Chow C.C., Yeung V.T., et al. Accuracy, precision and user-acceptability of self blood glucose monitoring machines. Diabetes Res Clin Pract 1997;36:91-104 (Pubitemid 27297002)
118. Kabadi U.M., O'Connell K.M., Johnson J., Kabadi M. The effect of recurrent practice at home on the acceptability of capillary blood glucose readings. Accuracy of self blood glucose testing. Diabetes Care 1994;17:1110-1123
119. Burnett R.W., D'Orazio P., Fogh-Andersen N., Kuwa K., Kulpmann W.R., Larsson L., et al. IFCC recommendation on reporting results for blood glucose. Clin Chim Acta 2001;307:205-209 (Pubitemid 32448926)
120. D'Orazio P., Burnett R.W., Fogh-Andersen N., Jacobs E., Kuwa K., Kulpmann W.R., et al. Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem 2005;51:1573-1576 (Pubitemid 41233089)
121. Steffes M.W., Sacks D.B. Measurement of circulating glucose concentrations: The time is now for consistency among methods and types of samples. Clin Chem 2005;51:1569-1570 (Pubitemid 41233087)
122. Weitgasser R., Gappmayer B., Pichler M. Newer portable glucosemeters - analytical improvement compared with previous generation devices? Clin Chem 1999;45:1821-1825 (Pubitemid 29477341)
123. Bohme P., Floriot M., Sirveaux M.A., Durain D., Ziegler O., Drouin P., Guerci B. Evolution of analytical performance in portable glucose meters in the last decade. Diabetes Care 2003;26:1170-1175 (Pubitemid 36929267)
124. Skeie S., Thue G., Nerhus K., Sandberg S. Instruments for self-monitoring of blood glucose: Comparisons of testing quality achieved by patients and a technician. Clin Chem 2002;48:994-1003 (Pubitemid 34680893)
125. ADA. Consensus statement on self-monitoring of blood glucose. Diabetes Care 1987;10:93-99
126. NCCLS. Ancillary (bedside) blood glucose testing in acute and chronic care facilities; approved guideline C30-A. Villanova (PA): NCCLS; 1994; 14:1-14
127. ISO. In vitro diagnostic test systems - requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Geneva: ISO; 2003. ISO 15197:2003; 1st ed. 2003-05-01
128. Clarke W.L., Cox D., Gonder-Frederick L.A., Carter W., Pohl S.L. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care 1987;10:622-628 (Pubitemid 17158937)
129. Skeie S., Thue G., Sandberg S. Patientderived quality specifications for instruments used in self-monitoring of blood glucose. Clin Chem 2001;47:67-73 (Pubitemid 32064277)
130. Boyd J.C., Bruns D.E. Quality specifications for glucose meters: Assessment by simulation modeling of errors in insulin dose. Clin Chem 2001;47:209-214 (Pubitemid 32142918)
131. Novis D.A., Jones B.A. Interinstitutional comparison of bedside blood glucose monitoring program characteristics, accuracy performance, and quality control documentation: A College of American Pathologists Q-Probes study of bedside blood glucose monitoring performed in 226 small hospitals. Arch Pathol Lab Med 1998;122: 495-502 (Pubitemid 28262179)
132. Brunner G.A., Ellmerer M., Sendlhofer G., Wutte A., Trajanoski Z., Schaupp L., et al. Validation of home blood glucose meters with respect to clinical and analytical approaches. Diabetes Care 1998;21:585-590 (Pubitemid 28172939)
133. Weinzimer S.A., Beck R.W., Chase H.P., Fox L.A., Buckingham B.A., Tamborlane W.V., et al. Accuracy of newer-generation home blood glucose meters in a Diabetes Research in Children Network (DirecNet) inpatient exercise study. Diabetes Technol Ther 2005;7:675-680; discussion 681-3
134. Mahoney J., Ellison J. Assessing the quality of glucose monitor studies: A critical evaluation of published reports. Clin Chem 2007;53:1122-1128 (Pubitemid 46867530)
135. Kristensen G.B., Nerhus K., Thue G., Sandberg S. Standardized evaluation of instruments for self-monitoring of blood glucose by patients and a technologist. Clin Chem 2004;50:1068-1071 (Pubitemid 38725800)
136. Wiener R.S., Wiener D.C., Larson R.J. Benefits and risks of tight glucose control in critically ill adults: A meta-analysis. JAMA 2008;300:933-944
137. Scott M.G., Bruns D.E., Boyd J.C., Sacks D.B. Tight glucose control in the intensive care unit: Are glucose meters up to the task? Clin Chem 2009;55:18-20
138. Dungan K., Chapman J., Braithwaite S.S., Buse J. Glucose measurement: Confounding issues in setting targets for inpatient management. Diabetes Care 2007;30:403-409 (Pubitemid 46198356)
139. Boyd J.C., Bruns D.E. Monte Carlo simulation in establishing analytical quality requirements for clinical laboratory tests meeting clinical needs. Methods Enzymol 2009;467:411-433
140. Finkielman J.D., Oyen L.J., Afessa B. Agreement between bedside blood and plasma glucose measurement in the ICU setting. Chest 2005;127:1749-1751 (Pubitemid 46218804)
141. Hoedemaekers C.W., Klein Gunnewiek J.M., Prinsen M.A., Willems J.L., Van der Hoeven J.G. Accuracy of bedside glucose measurement from three glucometers in critically ill patients. Crit Care Med 2008;36:3062-3066
142. Meynaar I.A., Van Spreuwel M., Tangkau P.L., Dawson L., Sleeswijk Visser S., et al. Accuracy of AccuChek glucose measurement in intensive care patients. Crit Care Med 2009;37:2691-2696
143. Kanji S., Buffie J., Hutton B., Bunting P.S., Singh A., McDonald K., et al. Reliability of point-of-care testing for glucose measurement in critically ill adults. Crit Care Med 2005;33:2778-2785 (Pubitemid 41816412)
144. Schiffrin A., Belmonte M. Multiple daily self-glucose monitoring: Its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. Diabetes Care 1982;5:479-484 (Pubitemid 12015085)
145. Nathan D. The importance of intensive supervision in determining the efficacy of insulin pump therapy. Diabetes Care 1983;6: 295-7
146. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995;333:1237-1241
147. Goldstein D.E., Little R.R., Lorenz R.A., Malone J.I., Nathan D., Peterson C.M., Sacks D.B. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761-1773 (Pubitemid 38857461)
148. Garg S., Zisser H., Schwartz S., Bailey T., Kaplan R., Ellis S., Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: A randomized controlled trial. Diabetes Care 2006;29:44-50 (Pubitemid 44033429)
149. Chetty V.T., Almulla A., Odueyungbo A., Thabane L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood fingerstick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in type I diabetic patients: A systematic review. Diabetes Res Clin Pract 2008;81:79-87
150. Tamborlane W.V., Beck R.W., Bode B.W., Buckingham B., Chase H.P., Clemons R., et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl JMed 2008;359:1464-1476
151. Haupt K., Mosbach K. Plastic antibodies: Developments and applications. Trends Biotechnol 1998;16:468-475 (Pubitemid 28532703)
152. Chen G., Guan Z., Chen C.T., Fu L., Sundaresan V., Arnold F.H. A glucosesensing polymer. Nat Biotechnol 1997;15:354-357
153. James T.D., Sandanayake K.R.A.S., Shinkai S. A glucose-selective molecular fluorescence sensor. Angew Chem Int Ed Engl 1994;33:2207-2209 (Pubitemid 24986814)
154. Birch D.J.S., Imhof R.E. Time-domain fluorescence spectroscopy using time-correlated single-photon counting. Top Fluoresc Spectrosc 1994;1:1-95
155. Tolosa L., Szmacinski H., Rao G., Lakowicz J.R. Lifetime-based sensing of glucose using energy transfer with a long lifetime donor. Anal Biochem 1997;250:102-108 (Pubitemid 27310318)
156. Rolinski O.J., Birch D.J.S., McCartney L.J., Pickup J.C. Near-infrared assay for glucose determination. Proc Soc Photo Opt Instrum Eng 1999;3602:6-14
157. Marvin J.S., Hellinga H.W. Engineering biosensors by introducing fluorescent allosteric signal transducers: Construction of a novel glucose sensor. J Am Chem Soc 1998;120:7-11 (Pubitemid 28046421)
158. Wentholt I.M., Vollebregt M.A., Hart A.A., Hoekstra J.B., DeVries J.H. Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care 2005;28:2871-2876 (Pubitemid 43942917)
159. Khalil O.S. Non-invasive glucose measurement technologies: An update from 1999 to the dawn of the new millennium. Diabetes Technol Ther 2004;6:660-697 (Pubitemid 39383073)
160. Arnold M.A., Small G.W. Noninvasive glucose sensing.Anal Chem 2005;77:5429-5439 (Pubitemid 41266033)
161. Tura A., Maran A., Pacini G. Non-invasive glucose monitoring: Assessment of technologies and devices according to quantitative criteria. Diabetes Res Clin Pract 2007;77:16-40 (Pubitemid 46590478)
162. Sieg A., Guy R.H., Delgado-Charro M.B. Noninvasive and minimally invasive methods for transdermal glucose monitoring. Diabetes Technol Ther 2005;7:174-197 (Pubitemid 40354587)
163. Kohl M., Essenpreis M., Cope M. The influence of glucose concentration upon the transport of light in tissue-simulating phantoms. Phys Med Biol 1995;40:1267-1287
164. Heise H.M., Lampen P. Transcutaneous glucose measurements using nearinfrared spectroscopy: Validation of statistical calibration models. Diabetes Care 2000;23:1208-1210
165. Gutman S., Bernhardt P., Pinkos A., Moxey-Mims M., Knott T., Cooper J. Regulatory aspects of noninvasive glucose measurements. Diabetes Technol Ther 2002;4:779-781 (Pubitemid 36169235)
166. Rhiel M.H., Amrhein M.I., Marison I.W., Von Stockar U. The influence of correlated calibration samples on the prediction performance of multivariate models based on mid-infrared spectra of animal cell cultures. Anal Chem 2002;74:5227-5236 (Pubitemid 35215350)
167. Arnold M.A., Liu L., Olesberg J.T. Selectivity assessment of noninvasive glucose measurements based on analysis of multivariate calibration vectors. J Diabetes Sci Technol 2007;1:454-462
168. Small G.W. Chemometrics and nearinfrared spectroscopy: Avoiding the pitfalls. Trends Anal Chem 2006;25:1057-1066 (Pubitemid 44821416)
169. Gabrielsson J., Trygg J. Recent developments in multivariate calibration. Crit Rev Anal Chem 2006;36:243-255 (Pubitemid 44889530)
170. Arnold M.A., Small G.W., Xiang D., Qui J., Murhammer D.W. Pure component selectivity analysis of multivariate calibration models from near-infrared spectra. Anal Chem 2004;76:2583-2590 (Pubitemid 38585727)
171. Arnold M.A., Olesberg J.T., Small G.W. Near-infrared spectroscopy for non-invasive glucose sensing. In: Cunningham D, Stenken JA, eds. Analytical chemistry of in vivo glucose measurements. Hoboken, NJ: John Wiley & Sons; 2009. p 357-390
172. Shih W-C, Bechtel K.B., Feld M.S. Noninvasive glucose sensing with Raman spectroscopy. In: Cunningham D, Stenken JA, eds. Analytical chemistry of in vivo glucose measurements. Hoboken, NJ: John Wiley & Sons; 2009. p 391- 419
173. Lawrence J.M., Contreras R., Chen W., Sacks D.A. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 2008;31:899-904
174. Crowther C.A., Hiller J.E., Moss J.R., McPhee A.J., Jeffries W.S., Robinson J.S. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352:2477-2486 (Pubitemid 41007863)
175. Landon M.B., Spong C.Y., Thom E., Carpenter M.W., Ramin S.M., Casey B., et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009;361:1339-1348
176. Metzger B.E., Lowe L.P., Dyer A.R., Trimble E.R., Chaovarindr U., Coustan D.R., et al. Hyperglycemia and adverse pregnancy outcomes. N Engl JMed 2008;358:1991-2002
177. HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: Associations with neonatal anthropometrics. Diabetes 2009;58:453-459
178. International Association of Diabetes and Pregnancy Study Groups. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676-682
179. Kim C., Newton K.M., Knopp R.H. Gestational diabetes and the incidence of type 2 diabetes: A systematic review. Diabetes Care 2002;25:1862-1868
180. ADA. Tests of glycemia in diabetes. Diabetes Care 1999;22(Suppl. 1):S77-S79
181. Sacks D.B. Diabetes mellitus. In: Burtis CA, Ash-wood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. St. Louis: Elsevier Saunders. Accepted; forthcoming 2012
182. Kitabchi A.E., Umpierrez G.E., Murphy M.B., Barrett E.J., Kreisberg R.A., Malone J.I., Wall B.M. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(Suppl. 1):S94-102
183. Kreisberg R.A. Diabetic ketoacidosis: New concepts and trends in pathogenesis and treatment. Ann Intern Med 1978;88:681-695 (Pubitemid 8339956)
184. Owen O.E., Trapp V.E., Skutches C.L., Mozzoli M.A., Hoeldtke R.D., Boden G., Reichard G.A. Jr. Acetone metabolism during diabetic ketoacidosis. Diabetes 1982;31:242-248 (Pubitemid 12170296)
185. Stephens J.M., Sulway M.J., Watkins P.J. Relationship of blood acetoacetate and 3-hydroxybutyrate in diabetes. Diabetes 1971;20:485-489
186. Porter W.H., Yao H.H., Karounos D.G. Laboratory and clinical evaluation of assays for beta-hydroxybutyrate. Am J Clin Pathol 1997;107:353-358 (Pubitemid 27090241)
187. ADA. Tests of glycemia in diabetes [Position statement]. Diabetes Care 2000;23(Suppl. 1):S80-S82
188. Csako G. Causes, consequences, and recognition of false-positive reactions for ketones. Clin Chem 1990;36:1388-1389 (Pubitemid 20251961)
189. Rosenbloom A.L., Malone J.I. Recognition of impending ketoacidosis delayed by ketone reagent strip failure. JAMA 1978;240:2462-2464
190. McMurray C.H., Blanchflower W.J., Rice D.A. Automated kinetic method for D- 3-hydroxybutyrate in plasma or serum. Clin Chem 1984;30:421-425
191. Koch D.D., Feldbruegge D.H. Optimized kinetic method for automated determination of beta-hydroxybutyrate. Clin Chem 1987;33:1761-1766 (Pubitemid 19097539)
192. D'arrigo T. Beyond blood glucose. Diabetes Forecast 1999;52:37-38
193. Westphal S.A. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. Am J Med 1996;101:19-24 (Pubitemid 26285936)
194. Wiggam M.I., O'Kane M.J., Harper R., Atkinson A.B., Hadden D.R., Trimble E.R., Bell P.M. Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. Diabetes Care 1997;20:1347-1352 (Pubitemid 27366804)
195. Umpierrez G.E., Watts N.B., Phillips L.S. Clinical utility of beta-hydroxybutyrate determined by reflectance meter in the management of diabetic ketoacidosis. Diabetes Care 1995;18:137-138
196. Noyes K.J., Crofton P., Bath L.E., Holmes A., Stark L., Oxley C.D., Kelnar C.J. Hydroxybutyrate near-patient testing to evaluate a new end-point for intravenous insulin therapy in the treatment of diabetic ketoacidosis in children. Pediatr Diabetes 2007;8:150-156 (Pubitemid 46864296)
197. ADA. Implications of the Diabetes Control and Complications Trial [Position statement]. Diabetes Care 2000;23(Suppl. 1):S24-S26
198. Kitzmiller J.L., Block J.M., Brown F.M., Catalano P.M., Conway D.L., Coustan D.R., et al. Managing preexisting diabetes for pregnancy: Summary of evidence and consensus recommendations for care. Diabetes Care 2008;31:1060-1079
199. Davidson M.B. Diabetes research and diabetes care. Where do we stand? Diabetes Care 1998;21:2152-2160
200. A.D.A. Provider Notes: the newsletter of the ADA/NCQA Provider Recognition Program. Provid Notes 2000;1:1-4
201. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., Zinman B. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-1721 (Pubitemid 44025023)
202. Qaseem A., Vijan S., Snow V., Cross J.T., Weiss K.B., Owens D.K. Glycemic control and type 2 diabetes mellitus: The optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 2007;147:417-422 (Pubitemid 351664542)
203. Bunn H.F. Nonenzymatic glycosylation of protein: Relevance to diabetes. Am J Med 1981;70:325-330 (Pubitemid 11146018)
204. Goldstein D.E., Little R.R., Wiedmeyer H.M., England J.D., McKenzie E.M. Glycated hemoglobin: Methodologies and clinical applications. Clin Chem 1986;32:B64-B70
205. Svendsen P.A., Lauritzen T., Soegaard U., Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. Diabetologia 1982;23:403-405 (Pubitemid 12037379)
206. Cefalu W.T., Wang Z.Q., Bell-Farrow A., Kiger F.D., Izlar C. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem 1994;40:1317-1321 (Pubitemid 24205951)
207. Murata G.H., Hoffman R.M., Duckworth W.C., Wendel C.S., Shah J.H. Contributions of weekly mean blood glucose values to hemoglobin A1c in insulintreated type 2 diabetes: The Diabetes Outcomes in Veterans Study (DOVES). Am J Med Sci 2004;327:319-323 (Pubitemid 38780175)
208. Nathan D.M., Turgeon H., Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007;50:2239-2244 (Pubitemid 47512407)
209. Nathan D.M., Kuenen J., Borg R., Zheng H., Schoenfeld D., Heine R.J. Translating the hemoglobin A1c assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478
210. Baker J.R., Johnson R.N., Scott D.J. Serum fructosamine concentrations in patients with type II (non-insulin-dependent) diabetes mellitus during changes in management. Br Med J (Clin Res Ed) 1984;288:1484-1486 (Pubitemid 14121864)
211. Tahara Y., Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995;18:440-447
212. Little R.R., Wiedmeyer H.M., England J.D., Wilke A.L., Rohlfing C.L., Wians F.H. Jr, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem 1992;38:2472-2478 (Pubitemid 23006216)
213. Bodor G.S., Little R.R., Garrett N., Brown W., Goldstein D.E., Nahm M.H. Standardization of glycohemoglobin determinations in the clinical laboratory: Three years of experience. Clin Chem 1992;38:2414-2418 (Pubitemid 23006203)
214. Weykamp C.W., Penders T.J., Muskiet F.A., Van der Slik W. Effect of calibration on dispersion of glycohemoglobin values determined by 111 laboratories using 21 methods. Clin Chem 1994;40:138-144 (Pubitemid 24050226)
215. Goldstein D.E., Little R.R. Bringing order to chaos: The National Glycohemoglobin Standardization Program. Contemp Int Med 1997;9:27-32
216. Little R.R., Rohlfing C.L., Wiedmeyer H.M., Myers G.L., Sacks D.B., Goldstein D.E. The National Glycohemoglobin Standardization Program: A five-year progress report. Clin Chem 2001;47:1985-1992 (Pubitemid 33010715)
217. DCCT. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: A multicenter study. Clin Chem 1987;33:2267-2271
218. Little R.R., Rohlfing C.L., Sacks D.B. Status of HbA1c measurement and goals for improvement: From chaos to order for improving diabetes care. Clin Chem 2011;57:205-214
219. Jeppsson J.O., Kobold U., Barr J., Finke A., Hoelzel W., Hoshino T., et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78-89 (Pubitemid 34196455)
220. Hoelzel W., Weykamp C., Jeppsson J.O., Miedema K., Barr J.R., Goodall I., et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: A method-comparison study. Clin Chem 2004;50:166-174 (Pubitemid 38125714)
221. Weykamp C., John W.G., Mosca A., Hoshino T., Little R., Jeppsson J., et al. The IFCC reference measurement system for HbA1c: A 6-year progress report. Clin Chem 2008;54:240-248 (Pubitemid 351302616)
222. Sacks D.B. Translating hemoglobin A1c into average blood glucose: Implications for clinical chemistry. Clin Chem 2008; 54:1756-1758
223. Hanas R., John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Clin Chem 2010;56:1362-1364
224. Pani L.N., Korenda L., Meigs J.B., Driver C., Cha-many S., Fox C.S., et al. Effect of aging on A1C levels in individuals without diabetes: Evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001- 2004. Diabetes Care 2008;31:1991-1996
225. Ziemer D.C., Kolm P., Weintraub W.S., Vaccarino V., Rhee M.K., Twombly J.G., et al. Glucose-independent, black-white differences in hemoglobin A1c levels: A cross-sectional analysis of 2 studies. Ann Intern Med 2010;152:770-777
226. Little R.R., Sacks D.B. HbA1c: How do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes 2009;16:113-118
227. Herman W.H., Ma Y., Uwaifo G., Haffner S., Kahn S.E., Horton E.S., et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007;30:2453-2457 (Pubitemid 47547771)
228. Saaddine J.B., Fagot-Campagna A., Rolka D., Narayan K.M., Geiss L., Eberhardt M., Flegal K.M. Distribution of HbA1c levels for children and young adults in the U.S.: Third National Health and Nutrition Examination Survey. Diabetes Care 2002;25:1326-1330 (Pubitemid 41071140)
229. Selvin E., Steffes M.W., Zhu H., Matsushita K., Wagenknecht L., Pankow J., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.NEngl J Med 2010;362:800-811
230. Davie S.J., Gould B.J., Yudkin J.S. Effects of vitamin C on glycosylation of proteins. Diabetes 1992;41:167-173
231. Ceriello A., Giugliano D., Quatraro A., Donzella C., Dipalo G., Lefebvre P.J. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? Diabetes Care 1991;14:68-72
232. Tarim O., Kucukerdogan A., Gunay U., Eralp O., Ercan I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int 1999;41:357-362 (Pubitemid 29376974)
233. Bry L., Chen P.C., Sacks D.B. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin [Review]. Clin Chem 2001;47:153-163 (Pubitemid 32142912)
234. Roberts W.L., Chiasera J.M., Ward-Cook K.M. Glycohemoglobin results in samples with hemoglobin C or S trait: A comparison of four test systems. Clin Chem1999;45:906-909 (Pubitemid 29266625)
235. Weykamp C.W., Penders T.J., Muskiet F.A., Van der Slik W. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993;39:1717-1723 (Pubitemid 23246008)
236. Schnedl W.J., Krause R., Halwachs- Baumann G, Trinker M, Lipp RW, Krejs GJ. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care 2000;23:339-344 (Pubitemid 30131741)
237. Rendell M., Brannan C., Nierenberg J., Rasbold K., Hestorff T. Fingerstick glycosylated hemoglobin, plasma protein, and albumin. Diabetes Care 1987;10:629-632 (Pubitemid 17158938)
238. Ferrell R.E., Hanis C.L., Aguilar L., Tulloch B., Garcia C., Schull W.J. Glycosylated hemoglobin determination from capillary blood samples. Utility in an epidemiologic survey of diabetes. Am J Epidemiol 1984;119:159-166 (Pubitemid 14186710)
239. Little R.R., England J.D., Wiedmeyer H.M., Goldstein D.E. Effects of whole blood storage on results for glycosylated hemoglobin as measured by ion-exchange chromatography, affinity chromatography, and colorimetry. Clin Chem 1983;29:1113-1115 (Pubitemid 13106896)
240. Little R.R., Rohlfing C.L., Tennill A.L., Connolly S., Hanson S. Effects of sample storage conditions on glycated hemoglobin measurement: Evaluation of five different high performance liquid chromatography methods. Diabetes Technol Ther 2007;9:36-42
241. Baglin S.K., Brown A.S. Two capillary blood-collection techniques for estimating glycohemoglobin compared. Clin Chem 1995;41:330-332
242. Voss E.M., Cembrowski G.S., Clasen B.L., Spencer M.L., Ainslie M.B., Haig B. Evaluation of capillary collection system for HbA1c specimens. Diabetes Care 1992;15:700-701
243. Little R.R., Wiedmeyer H.M., Huang D.H., Goldstein D.E., Parson R.G., Kowal R., et al. A simple blood collection device for analysis of glycohemoglobin (GHB). Clin Chem 1998;44:A139
244. Baynes J.W., Bunn H.F., Goldstein D., Harris M., Martin D.B., Peterson C., Winterhalter K. National Diabetes Data Group: Report of the expert committee on glucosylated hemoglobin. Diabetes Care 1984;7:602-606 (Pubitemid 15210467)
245. Marshall S.M., Barth J.H. Standardization of HbA1c measurements: A consensus statement. Ann Clin Biochem 2000;37:45-46 (Pubitemid 30064223)
246. 1c analysis - precision, accuracy and standardisation: consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA). Clin Chem Lab Med 2007;45:1083-1097
247. Sacks D.B. CAP surveys: participant summary for glycohemoglobin survey 2010 set GH2-A. Northfield, IL: College of American Pathologists; 2010
248. Goldstein D.E., Peth S.B., England J.D., Hess R.L., Da Costa J. Effects of acute changes in blood glucose on HbA1c. Diabetes 1980;29:623-628 (Pubitemid 12201308)
249. Cagliero E., Levina E.V., Nathan D.M. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care 1999;22:1785-1789 (Pubitemid 29521862)
250. Kennedy L., Herman W.H., Strange P., Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2006;29:1-8 (Pubitemid 44033422)
251. Khunti K., Stone M.A., Burden A.C., Turner D., Raymond N.T., Burden M., Baker R. Randomised controlled trial of near-patient testing for glycated haemoglobin in people with type 2 diabetes mellitus. Br J Gen Pract 2006;56:511-517 (Pubitemid 43984468)
252. Larsen M.L., Horder M., Mogensen E.F. Effect of long-term monitoring of glycosylated hemoglobin levels in insulindependent diabetes mellitus. N Engl J Med 1990;323:1021-1025 (Pubitemid 20336960)
253. Davidson M.B., Peters A.L., Schriger D.L. An alternative approach to the diagnosis of diabetes with a review of the literature. Diabetes Care 1995;18:1065-1071
254. Lenters-Westra E., Slingerland R.J. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem 2010;56:44-52
255. American Association of Clinical Endocrinologists Board of Directors/American College of Endocrinologists Board of Trustees. American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract 2010;16:155-156
256. Makita Z., Radoff S., Rayfield E.J., Yang Z., Skolnik E., Delaney V., et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842
257. Monnier V.M., Bautista O., Kenny D., Sell D.R., Fogarty J., Dahms W., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: Relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870-880 (Pubitemid 29153089)
258. Murphy R., Ellard S., Hattersley A.T. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008;4:200-213 (Pubitemid 351430925)
259. Edghill E.L., Flanagan S.E., Patch A.M., Boustred C., Parrish A., Shields B., et al. Insulin mutation screening in 1,044 patients with diabetes: Mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008;57:1034-1042
260. Stoy J., Greeley S.A., Paz V.P., Ye H., Pastore A.N., Skowron K.B., et al. Diagnosis and treatment of neonatal diabetes: A United States experience. Pediatr Diabetes 2008;9:450-459
261. Fajans S.S., Bell G.I., Polonsky K.S. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-980
262. Graham J., Hagopian W.A., Kockum I., Li L.S., Sanjeevi C.B., Lowe R.M., et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002;51:1346-1355 (Pubitemid 34826598)
263. Concannon P., Rich S.S., Nepom G.T. Genetics of type 1A diabetes. N Engl J Med 2009;360:1646-1654
264. Nagi D.K., Hendra T.J., Ryle A.J., Cooper T.M., Temple R.C., Clark P.M., et al. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990;33:532-537 (Pubitemid 20293159)
265. Barrett J.C., Clayton D.G., Concannon P., Akolkar B., Cooper J.D., Erlich H.A., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009;41:703-707
266. Nadler S.T., Stoehr J.P., Schueler K.L., Tanimoto G., Yandell B.S., Attie A.D. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 2000;97:11371-11376
267. Ziegler A.G., Bachmann W., Rabl W. Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. Diabetes Metab Rev 1993;9:289-293 (Pubitemid 24160208)
268. Rewers M., Bugawan T.L., Norris J.M., Blair A., Beaty B., Hoffman M., et al. Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 1996;39:807-812 (Pubitemid 26228110)
269. Hagopian W.A., Lernmark A., Rewers M.J., Simell O.G., She J.X., Ziegler A.G., et al. TEDDY-The Environmental Determinants of Diabetes in the Young: An observational clinical trial. Ann N Y Acad Sci 2006;1079:320-326 (Pubitemid 44968741)
270. Kukreja A., Maclaren N.K. Autoimmunity and diabetes. J Clin Endocrinol Metab 1999;84:4371-4378
271. Barker J.M., Goehrig S.H., Barriga K., Hoffman M., Slover R., Eisenbarth G.S., et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004;27:1399-1404 (Pubitemid 38679990)
272. Saxena R., Voight B.F., Lyssenko V., Burtt N.P., De Bakker P.I., Chen H., et al. Genomewide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-1336 (Pubitemid 46871653)
273. Scott L.J., Mohlke K.L., Bonnycastle L.L., Willer C.J., Li Y., Duren W.L., et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-1345 (Pubitemid 46871655)
274. Meigs J.B., Shrader P., Sullivan L.M., McAteer J.B., Fox C.S., Dupuis J., et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl JMed 2008;359:2208-2219
275. Klein J., Sato A. The HLA system. First of two parts. N Engl J Med 2000;343:702-709
276. Taylor S.I., Arioglu E. Genetically defined forms of diabetes in children. J Clin Endocrinol Metab 1999;84:4390-4396
277. Fajans S.S., Bell G.I., Bowden D.W., Halter J.B., Polonsky K.S. Maturity onset diabetes of the young (MODY). Diabet Med 1996;13:S90-S95 (Pubitemid 26316208)
278. Todd J.A. Genetics of type 1 diabetes. Pathol Biol (Paris) 1997;45:219-227 (Pubitemid 27207335)
279. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229 (Pubitemid 32718550)
280. Harrison L.C. Risk assessment, prediction and prevention of type 1 diabetes. Pediatr Diabetes 2001;2:71-82 (Pubitemid 32577161)
281. Redondo M.J., Kawasaki E., Mulgrew C.L., Noble J.A., Erlich H.A., Freed B.M., et al. DRand DQ-associated protection from type 1A diabetes: Comparison of DRB1*1401 and DQA1*0102-DQB1*0602*. J Clin Endocrinol Metab 2000;85:3793-3797
282. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-678
283. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007;39:857-864 (Pubitemid 47018195)
284. Maclaren N.K., Kukreja A. Type 1 diabetes. In: Sly WS, ed. The metabolic and molecular bases of inherited disease. 8th ed. St. Louis: McGraw-Hill; 2001. p 1471-1488
285. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553 (Pubitemid 28319935)
286. Palmer J.P., Asplin C.M., Clemons P., Lyen K., Tatpati O., Raghu P.K., Paquette T.L. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983;222:1337-1339 (Pubitemid 14204704)
287. Baekkeskov S., Aanstoot H.J., Christgau S., Reetz A., Solimena M., Cascalho M., et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990;347:151-6; erratum 1990;347:728
288. Kaufman D.L., Erlander M.G., Clare-Salzler M., Atkinson M.A.,Maclaren N.K., Tobin A.J. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992;89:283-292
289. Atkinson M.A., Maclaren N.K. Islet cell autoantigens in insulin-dependent diabetes. J Clin Invest 1993;92:1608-1616 (Pubitemid 23304521)
290. Lan M.S., Wasserfall C., Maclaren N.K., Notkins A.L. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulindependent diabetes mellitus. Proc Natl Acad Sci U S A 1996;93:6367-6370 (Pubitemid 26230311)
291. Lu J., Li Q., Xie H., Chen Z.J., Borovitskaya A.E., Maclaren N.K., et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: Precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A 1996;93:2307-2311
292. Wenzlau J.M., Juhl K., Yu L., Moua O., Sarkar S.A., Gottlieb P., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-17045 (Pubitemid 350210987)
293. Wenzlau J.M., Liu Y., Yu L., Moua O., Fowler K.T., Rangasamy S., et al. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008;57:2693-2697
294. Patterson C.C., Dahlquist G.G., Gyurus E., Green A., Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: A multicentre prospective registration study. Lancet 2009;373:2027-2033
295. Maclaren N., Lan M., Coutant R., Schatz D., Silverstein J., Muir A., et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (type 1) diabetes in relatives. J Autoimmun 1999;12:279-287 (Pubitemid 29261964)
296. Verge C.F., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Jackson R.A., et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/ IA-2 autoantibodies. Diabetes 1996;45:926-933 (Pubitemid 26225509)
297. Schott M., Schatz D., Atkinson M., Krischer J., Mehta H., Vold B., Maclaren N. GAD65 autoantibodies increase the predictability but not the sensitivity of islet cell and insulin autoantibodies for developing insulin dependent diabetes mellitus. J Autoimmun 1994;7:865-872 (Pubitemid 24378370)
298. Turner R., Stratton I., Horton V., Manley S., Zimmet P., Mackay I.R., et al. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group [published erratum appears in Lancet 1998;351:376]. Lancet 1997;350:1288-1293 (Pubitemid 28036638)
299. Pozzilli P., Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (Latent Autoimmune Diabetes of the Adult): Definition, characterization, and potential prevention. Diabetes Care 2001;24:1460-1467 (Pubitemid 33716438)
300. Palmer J.P., Hampe C.S., Chiu H., Goel A., Brooks-Worrell B.M. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005;54(Suppl. 2):S62-S67 (Pubitemid 43343332)
301. Kobayashi T., Tanaka S., Harii N., Aida K., Shimura H., Ohmori M., et al. Immunopathological and genetic features in slowly progressive insulin-dependent diabetes mellitus and latent autoimmune diabetes in adults. Ann N Y Acad Sci 2006;1079:60-66 (Pubitemid 44968702)
302. Braghi S., Bonifacio E., Secchi A., Di Carlo V., Pozza G., Bosi E. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patientswith type 1 diabetes. Diabetes 2000;49:218-224 (Pubitemid 30071000)
303. Zimmet P., Turner R., McCarty D., Rowley M., Mackay I. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999;22(Suppl. 2):B59-B64 (Pubitemid 29107150)
304. Petersen J.S., Dyrberg T., Damm P., Kuhl C., Molsted-Pedersen L., Buschard K. GAD65 autoantibodies in women with gestational or insulin dependent diabetes mellitus diagnosed during pregnancy. Diabetologia 1996;39:1329-1333 (Pubitemid 26356062)
305. Fuchtenbusch M., Ferber K., Standl E., Ziegler A.G. Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: A prospective multicenter study. Diabetes 1997;46:1459-1467 (Pubitemid 27369084)
306. Diabetes Prevention Trial-Type 1 Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
307. Siljander H., Harkonen T., Hermann R., Simell S., Hekkala A., Salonsaari R.T., et al. Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab Res Rev 2009;25:615-622
308. Williams A.J., Bingley P.J., Bonifacio E., Palmer J.P., Gale E.A. A novel micro-assay for insulin autoantibodies. J Autoimmun 1997;10:473-478 (Pubitemid 27433643)
309. Bingley P.J., Bonifacio E., Mueller P.W. Diabetes Antibody Standardization Program: First assay proficiency evaluation. Diabetes 2003;52:1128-1136 (Pubitemid 36523346)
310. Grubin C.E., Daniels T., Toivola B., Landin-Olsson M., Hagopian W.A., Li L., et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994;37:344-350 (Pubitemid 24113564)
311. Torn C., Mueller P.W., Schlosser M., Bonifacio E., Bingley P.J. Diabetes Antibody Standardization Program: Evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51:846-852
312. Mire-Sluis A.R., Gaines Das R., Lernmark A. The World Health Organization International Collaborative Study for islet cell antibodies. Diabetologia 2000;43:1282-1292
313. Gleichmann H., Bottazzo G.F. Progress toward standardization of
314. Verge C.F., Stenger D., Bonifacio E., Colman P.G., Pilcher C., Bingley P.J., Eisenbarth G.S. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998;47:1857-1866 (Pubitemid 28549191)
315. Ellis T.M., Schatz D.A., Ottendorfer E.W., Lan M.S., Wasserfall C., Salisbury P.J., et al. The relationship between humoral and cellular immunity to IA-2 in IDDM. Diabetes 1998;47:566-569 (Pubitemid 28160446)
316. Atkinson M.A., Bowman M.A., Campbell L., Darrow B.L., Kaufman D.L., Maclaren N.K. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes [see comments]. J Clin Invest 1994;94:2125-2129 (Pubitemid 24348254)
317. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
318. Nanto-Salonen K., Kupila A., Simell S., Siljander H., Salonsaari T., Hekkala A., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. Lancet 2008;372:1746-1755
319. Agardh C.D., Cilio C.M., Lethagen A., Lynch K., Leslie R.D., Palmer M., et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005;19:238-246 (Pubitemid 40910206)
320. Lernmark A., Agardh C.D. Immunomodulation with human recombinant autoantigens. Trends Immunol 2005;26:608-612 (Pubitemid 41726449)
321. ADA. Diabetes nephropathy. Diabetes Care 1999;22(Suppl. 1):S66-S69
322. Davidson M.B., Bazargan M., Bakris G., Peters Harmel A., Campese V., Basta E. ImmunoDip: An improved screening method for microalbuminuria. Am J Nephrol 2004;24:284-288 (Pubitemid 39070110)
323. Khosla N., Sarafidis P.A., Bakris G.L. Microalbuminuria. Clin Lab Med 2006;26:635-653, vi-vii (Pubitemid 44287154)
324. Sarafidis P.A., Riehle J., Bogojevic Z., Basta E., Chugh A., Bakris G.L. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol 2008;28:324-329
325. Levey A.S., De Jong P.E., Coresh J., Nahas M.E., Astor B.C., Matsushita K., et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int [Epub ahead of print 2010 Dec 8]
326. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S12-154
327. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L. Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252 (Pubitemid 37553153)
328. Klausen K.P., Scharling H., Jensen J.S. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med 2006;260:231-237 (Pubitemid 44253636)
329. Klausen K.P., Scharling H., Jensen G., Jensen J.S. New definition of microalbuminuria in hypertensive subjects: Association with incident coronary heart disease and death. Hypertension 2005;46:33-37 (Pubitemid 40946487)
330. Ratto E., Leoncini G., Viazzi F., Vaccaro V., Parodi A., Falqui V., et al. Microalbuminuria and cardiovascular risk assessment in primary hypertension: Should threshold levels be revised? Am J Hypertens 2006;19:728-734; discussion 735-6
331. Wachtell K., Ibsen H., Olsen M.H., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003;139:901-906
332. Rachmani R., Levi Z., Lidar M., Slavachevski I., Half-Onn E., Ravid M. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: Lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract 2000;49:187-194 (Pubitemid 30665465)
333. Pambianco G., Costacou T., Orchard T.J. The prediction of major outcomes of type 1 diabetes: A 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: A 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rateThe Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 2007;30:1248-1254 (Pubitemid 46684655)
334. Witte E.C., Lambers Heerspink H.J., De Zeeuw D., Bakker S.J., De Jong P.E., Gansevoort R. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009;20:436-443
335. Levey A.S., Coresh J., Greene T., Marsh J., Stevens L.A., Kusek J.W., Van Lente F. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-772 (Pubitemid 46580250)
336. Vassalotti J.A., Stevens L.A., Levey A.S. Testing for chronic kidney disease: A position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50:169-180 (Pubitemid 47095094)
337. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;293:1609-1616 (Pubitemid 40471791)
338. Yuyun M.F., Khaw K.T., Luben R., Welch A., Bingham S., Day N.E., Wareham N.J. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004;33:189-198 (Pubitemid 38500176)
339. Weir M.R., Bakris G.L. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010;31:469-470
340. Glassock R.J. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010;31:462-465;discussion 466-7
341. Steinke J.M., Sinaiko A.R., Kramer M.S., Suissa S., Chavers B.M., Mauer M. The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005;54:2164-2171 (Pubitemid 40911280)
342. Duka I., Bakris G. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens 2008;17:457-463
343. Schrier R.W., Estacio R.O., Mehler P.S., Hiatt W.R. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: A summary of the ABCD trial.Nat Clin Pract Nephrol 2007;3:428-438 (Pubitemid 47123588)
344. Ruggenenti P., Fassi A., Ilieva A.P., Bruno S., Iliev I.P., Brusegan V., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951 (Pubitemid 39447135)
345. Sinzinger H., Kritz H., Furberg C.D. Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance. Med Sci Monit 2003;9:PI88-PI92 (Pubitemid 37021477)
346. Incerti J., Zelmanovitz T., Camargo J.L., Gross J.L., De Azevedo M.J. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrol Dial Transplant 2005;20:2402-2407 (Pubitemid 41548863)
347. Lepore G., Maglio M.L., Nosari I., Dodesini A.R., Trevisan R. Cost-effectiveness of two screening programs for microalbuminuria in type 2 diabetes. Diabetes Care 2002;25:2103-2104; author reply 2104
348. Roberts W.L., Calcote C.B., Cook C.B., Gordon D.L., Moore M.L., Moore S., et al. Comparison of four commercial urinary albumin (microalbumin) methods: Implications for detecting diabetic nephropathy using random urine specimens. Clin Chim Acta 1998;273:21-33 (Pubitemid 29044052)
349. Howey J.E., Browning M.C., Fraser C.G. Biologic variation of urinary albumin: Consequences for analysis, specimen collection, interpretation of results, and screening programs. Am J Kidney Dis 1989;13:35-37 (Pubitemid 19035823)
350. Gansevoort R.T., Verhave J.C., Hillege H.L., Burgerhof J.G., Bakker S.J., De Zeeuw D., De Jong P.E. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005:S28-S35
351. Meinhardt U., Ammann R.A., Fluck C., Diem P., Mullis P.E. Microalbuminuria in diabetes mellitus: Efficacy of a new screening method in comparison with timed overnight urine collection. J Diabetes Complications 2003;17:254-257 (Pubitemid 37040771)
352. Poulsen P.L., Hansen B., Amby T., Terkelsen T., Mogensen C.E. Evaluation of a dipstick test for microalbuminuria in three different clinical settings, including the correlation with urinary albumin excretion rate. Diabetes Metab 1992;18:395-400 (Pubitemid 23045749)
353. Fernández-Fernández I., Páez Pinto J.M., Hermosín Bono T., Vázquez Garijo P., Ortiz Camuñez M.A., Tarilonte Delgado M.A. Rapid screening test evaluation for microalbuminuria in diabetes mellitus. Acta Diabetol 1998;35:199-202 (Pubitemid 29047934)
354. Leong S.O., Lui K.F., Ng W.Y., Thai A.C. The use of semi-quantitative urine test-strip (Micral Test) for microalbuminuria screening in patients with diabetes mellitus. Singapore Med J 1998;39:101-103 (Pubitemid 128518492)
355. Shaikh A., Seegmiller J.C., Borland T.M., Burns B.E., Ladwig P.M., Singh R.J., et al. Comparison between immunoturbidimetry, size-exclusion chromatography, and LC-MS to quantify urinary albumin. Clin Chem 2008;54:1504-1510
356. Lambers Heerspink H.J., Gansevoort R.T., Brenner B.M., Cooper M.E., Parving H.H., Shahinfar S., De Zeeuw D. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010;21:1355-1360
357. Ibsen H., Olsen M.H., Wachtell K., Borch-Johnsen K., LindholmL.H., Mogensen C.E., et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198-202 (Pubitemid 40179960)
358. Collins A.C., Sethi M., MacDonald F.A., Brown D., Viberti G.C. Storage temperature and differing methods of sample preparation in the measurement of urinary albumin. Diabetologia 1993;36:993-997 (Pubitemid 23288766)
359. MacNeil M.L., Mueller P.W., Caudill S.P., Steinberg K.K. Considerations when measuring urinary albumin: Precision, substances that may interfere, and conditions for sample storage. Clin Chem 1991;37:2120-2123
360. Hishiki S., Tochikubo O., Miyajima E., Ishii M. Circadian variation of urinary microalbumin excretion and ambulatory blood pressure in patients with essential hypertension. J Hypertens 1998;16:2101-2108 (Pubitemid 29002394)
361. Holl R.W., Grabert M., Thon A., Heinze E. Urinary excretion of albumin in adolescents with type 1 diabetes: Persistent versus intermittent microalbuminuria and relationship to duration of diabetes, sex, and metabolic control. Diabetes Care 1999;22:1555-1560 (Pubitemid 29418255)
362. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., Lupien P.J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-957 (Pubitemid 26114161)
363. Reaven G.M. Insulin resistance and its consequences; non-insulin dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental clinical text. Philadelphia: Lippincott- Raven; 1996. p 509-519
364. Chevenne D., Trivin F., Porquet D. Insulin assays and reference values. Diabetes Metab 1999;25:459-476 (Pubitemid 30003159)
365. Del Prato S. Measurement of insulin resistance in vivo. Drugs 1999;58:3-6;discussion 75-82
366. Wilson P.W., Meigs J.B., Sullivan L., Fox C.S., Nathan D.M., D'Agostino R.B. Sr. Prediction of incident diabetes mellitus in middle-aged adults: The Framingham Offspring Study. Arch Intern Med 2007;167:1068-1074 (Pubitemid 46835795)
367. Rutter M.K., Wilson P.W., Sullivan L.M., Fox C.S., D'Agostino R.B. Sr, Meigs J.B. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. Circulation 2008;117:1003-1009
368. Marks V. Recognition and differential diagnosis of spontaneous hypoglycaemia. Clin Endocrinol (Oxf) 1992;37:309-316
369. Marks V., Teale J.D. Hypoglycemia: Factitious and felonious. Endocrinol Metab Clin North Am 1999;28:579-601 (Pubitemid 29441323)
370. American College of Obstetrics and Gynecology. ACOG practice bulletin. Polycycstic ovary syndrome. Number 41, December 2002. Int J Gynaecol Obstet 2003;80:335-348
371. Robbins D.C., Andersen L., Bowsher R., Chance R., Dinesen B., Frank B., et al. Report of the American Diabetes Association's Task Force on Standardization of the Insulin Assay. Diabetes 1996;45:242-256
372. Marcovina S., Bowsher R.R., Miller W.G., Staten M., Myers G., Caudill S.P., et al. Standardization of insulin immunoassays: Report of the American Diabetes Association Workgroup. Clin Chem 2007;53:711-716 (Pubitemid 46580242)
373. Miller W.G., Thienpont L.M., Van Uytfanghe K., Clark P.M., Lindstedt P., Nilsson G., Steffes M.W. Toward standardization of insulin immunoassays. Clin Chem 2009;55:1011-1018
374. Staten M.A., Stern M.P., Miller W.G., Steffes M.W., Campbell S.E. Insulin assay standardization: Leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes Care 2010;33:205-206
375. Little R.R., Rohlfing C.L., Tennill A.L., Madsen R.W., Polonsky K.S., Myers G.L., et al. Standardization of C-peptide measurements. Clin Chem 2008;54:1023-1026 (Pubitemid 351793409)
376. Centers for Medicare and Medicaid Services. Infusion pumps: C-peptide levels as a criterion for use. Available from https://www.cms.gov/transmittals/ downloads/R513CP.pdf. Accessed March 2008
377. Burge M.R., Schade D.S. Insulins. Endocrinol Metab Clin North Am 1997;26:575-598 (Pubitemid 27411474)
378. ADA. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62-S69